New York: Portola Pharmaceuticals (NASDAQ:PTLA) Stock Has Just Had Its “Neutral” Rating Reiterated by Credit Suisse. Shares now Have a $30 Target

November 9, 2018 - By Ronnie Lemelle

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Logo

Investors sentiment increased to 1.53 in 2018 Q2. Its up 0.64, from 0.89 in 2018Q1. It is positive, as 16 investors sold Portola Pharmaceuticals, Inc. shares while 46 reduced holdings. 35 funds opened positions while 60 raised stakes. 60.58 million shares or 10.15% more from 55.00 million shares in 2018Q1 were reported.

Quantitative Systematic Strategies Lc owns 6,200 shares. The Denmark-based C Worldwide Grp Holdg A S has invested 0.08% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Panagora Asset Mngmt owns 6,336 shares. Rhumbline Advisers reported 63,060 shares stake. Prelude Capital Limited Company has 44,372 shares for 0.11% of their portfolio. Fisher Asset Mngmt Ltd Llc, a Washington-based fund reported 91,844 shares. Manufacturers Life Insur Co The reported 48,201 shares or 0% of all its holdings. Sphera Funds Ltd invested in 0.19% or 120,000 shares. 22,455 are owned by Profund Limited Liability Com. Kazazian Asset Ltd Liability invested 0.67% of its portfolio in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). Ascend Cap Limited has 207,113 shares for 0.37% of their portfolio. Fmr Ltd Liability Corporation owns 2.00M shares. 1,131 were reported by Piedmont Investment Advsr Limited Liability Com. Smith Asset Grp L P owns 5,360 shares. United Service Automobile Association has invested 0.01% in Portola Pharmaceuticals, Inc. (NASDAQ:PTLA).

Since June 6, 2018, it had 1 insider purchase, and 1 sale for $9.85 million activity. On Wednesday, June 6 Lis William sold $231,159 worth of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) or 5,113 shares.

Portola Pharmaceuticals (NASDAQ:PTLA) Rating Reaffirmed

Recently, In analysts note sent to investors and clients on 8 November, Portola Pharmaceuticals (NASDAQ:PTLA) shares have had their “Neutral” Rating maintained by equity analysts at Credit Suisse, who currently has a $30 target on company. This target by Credit Suisse suggests the possibile upside of 29.65 % from the last stock price.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Ratings Coverage

Among 4 analysts covering Portola Pharma (NASDAQ:PTLA), 2 have Buy rating, 0 Sell and 2 Hold. Therefore 50% are positive. Portola Pharma has $8000 highest and $28 lowest target. $49’s average target is 111.75% above currents $23.14 stock price. Portola Pharma had 6 analyst reports since May 17, 2018 according to SRatingsIntel. The rating was maintained by Morgan Stanley on Thursday, October 11 with “Equal-Weight”. The company was maintained on Friday, August 10 by Citigroup. As per Friday, August 10, the company rating was downgraded by Credit Suisse. Oppenheimer maintained Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Thursday, May 17. Oppenheimer has “Buy” rating and $8000 target. The company was maintained on Monday, August 13 by Morgan Stanley. Credit Suisse upgraded Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) rating on Monday, August 27. Credit Suisse has “Neutral” rating and $34 target.

The stock increased 21.41% or $4.08 during the last trading session, reaching $23.14. About 6.06M shares traded or 273.96% up from the average. Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) has declined 48.89% since November 9, 2017 and is downtrending. It has underperformed by 64.51% the S&P500.

Portola Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes therapeutics for patients in the areas of thrombosis, other hematologic disorders, and inflammation. The company has market cap of $1.53 billion. The firm is developing Betrixaban, an oral once-daily inhibitor of Factor Xa that is in Phase III clinical stage for extended duration VTE prophylaxis in acute medically ill patients for 35 days of in-hospital and post-discharge use; Andexanet alfa, a recombinant protein, which is in Phase III and IV stages for reverse anticoagulant activity in patients treated with fXa inhibitor; and Cerdulatinib, an orally available dual kinase inhibitor, which is in Phase IIa clinical stage for hematologic, blood, cancers, and inflammatory disorders. It currently has negative earnings. It also develops Syk-selective inhibitors in pre-clinical stage for allergic conjunctivitis.

More notable recent Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) news were published by: Benzinga.com which released: “The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Momenta Strikes Patent License Deal With AbbVie” on November 07, 2018, also Nasdaq.com with their article: “Portola Pharmaceuticals Reports Third Quarter 2018 Financial Results and Provides Corporate Update” published on November 07, 2018, Streetinsider.com published: “Pre-Open Movers 11/08: (CVNA) (PTLA) (CYBR) Higher; (VYGR) (KRO) (ZAYO) Lower (more…)” on November 08, 2018. More interesting news about Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) were released by: Nasdaq.com and their article: “Mid-Day Market Update: Dow Turns Higher; Koppers Holdings Shares Drop Following Weak Q3 Results” published on November 08, 2018 as well as Globenewswire.com‘s news article titled: “Portola Pharmaceuticals to Participate in Two Upcoming Investor Conferences” with publication date: November 06, 2018.

Portola Pharmaceuticals, Inc. (NASDAQ:PTLA) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.